




PHARMACEUTICAL 2022

Molecular Templates Inc.
Rank 350 of 466





PHARMACEUTICAL 2022

Molecular Templates Inc.
Rank 350 of 466

The relative strengths and weaknesses of Molecular Templates Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Molecular Templates Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Molecular Templates Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 19%, being 59% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	148,215
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,670
Liabilities, Non-Current	46,680
Other Assets	24,838
Other Compr. Net Income	-65
Other Expenses	3,369
Other Liabilities	33,350
Other Net Income	39,131
Other Revenues	0
Property and Equipment	19,309
Research and Development	84,665
Selling, General and Administrative Expense	34,106

Output Variable	Value in 1000 USD
Assets	192,362
Liabilities	126,700
Expenses	122,140
Revenues	0
Stockholders Equity	65,662
Net Income	-83,009
Comprehensive Net Income	-83,042
Economic Capital Ratio	19%